A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events. (Q37656386)

From Wikidata

Jump to navigation Jump to search

scientific article published on 18 March 2014

Language	Label	Description	Also known as
English	A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events.	scientific article published on 18 March 2014

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24638849%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events (English)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24638849%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

metastatic breast cancer

1 reference

based on heuristic

inferred from title

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24638849%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Sasha Mazzarello

12

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24638849%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

George Dranitsaris

13

object named as

George Dranitsaris

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24638849%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

16

object named as

Mark Clemons

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24638849%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Lisa Vandermeer

4

object named as

Lisa Vandermeer

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24638849%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

author name string

Christina L Addison

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24638849%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Nathaniel Bouganim

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24638849%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

John Hilton

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24638849%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Susan Dent

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24638849%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Sean Hopkins

7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24638849%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Iryna Kuchuk

8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24638849%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Roanne Segal

9

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24638849%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Xinni Song

10

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24638849%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Stan Gertler

11

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24638849%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Daylily Ooi

14

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24638849%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Gregory Pond

15

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24638849%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

language of work or name

0 references

publication date

18 March 2014

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24638849%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

number of pages

10

1 reference

based on heuristic

inferred from page(s)

Breast Cancer Research and Treatment

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24638849%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

144

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24638849%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24638849%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

615-624

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24638849%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

copyright license

Creative Commons Attribution-NonCommercial 4.0 International

18 March 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962742

6 September 2017

Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962742

6 September 2017

Time to put an end to the "one size fits all" approach to bisphosphonate use in patients with metastatic breast cancer?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962742

6 September 2017

Bone turnover markers: tools for prognosis and monitoring response to bisphosphonates?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962742

6 September 2017

Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962742

6 September 2017

Atrial Fibrillation and Stroke Associated With Intravenous Bisphosphonate Therapy in Older Patients With Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962742

6 September 2017

Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962742

6 September 2017

Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962742

6 September 2017

Bisphosphonates as treatment of bone metastases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962742

6 September 2017

Bisphosphonates and osteonecrosis of the jaws

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962742

6 September 2017

Use of intravenous bisphosphonates in older women with breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962742

6 September 2017

Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962742

6 September 2017

The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962742

6 September 2017

Determination of TGFbeta1 protein level in human primary breast cancers and its relationship with survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962742

6 September 2017

Moving into the future: treatment of bone metastases and beyond

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962742

6 September 2017

Do physicians follow systemic treatment and funding policy guidelines?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962742

6 September 2017

Activins and inhibins in endocrine and other tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962742

6 September 2017

Bone-targeted agents in the treatment of bone metastases: RANK outsider or new kid on the block?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962742

14 September 2017

Worst, average or current pain in the Brief Pain Inventory: which should be used to calculate the response to palliative radiotherapy in patients with bone metastases?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962742

14 September 2017

A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962742

14 September 2017

Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962742

1 September 2018

Randomized feasibility study of de-escalated (every 12 wk) versus standard (every 3 to 4 wk) intravenous pamidronate in women with low-risk bone metastases from breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962742

1 September 2018

In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962742

1 September 2018

Zoledronic acid and atrial fibrillation in cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962742

1 September 2018

Switching breast cancer patients with progressive bone metastases to third-generation bisphosphonates: measuring impact using the Functional Assessment of Cancer Therapy-Bone Pain

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962742

1 September 2018

Prevalence of renal insufficiency in breast cancer patients and related pharmacological issues

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962742

1 September 2018

In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962742

1 September 2018

Activin A circulating levels in patients with bone metastasis from breast or prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962742

1 September 2018

PINP as serum marker of metastatic spread to the bone in breast cancer patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962742

1 September 2018

Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962742

1 September 2018

Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962742

1 September 2018

Serum and tissue expression of activin a in postmenopausal women with breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962742

1 September 2018

Activin A is an essential cofactor for osteoclast induction.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3962742

1 September 2018

De-escalated administration of bone-targeted agents in patients with breast and prostate cancer-A survey of Canadian oncologists.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2906-X

21 January 2018

TGF-β signalling-related markers in cancer patients with bone metastasis

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-2906-X

21 January 2018

Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/24638849

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Elevated plasma levels of transforming growth factor-beta 1 (TGF-beta 1) in patients with advanced breast cancer: association with disease progression

1 reference

https://pubmed.ncbi.nlm.nih.gov/24638849

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bisphosphonate use for the management of breast cancer patients with bone metastases: a survey of Canadian Medical Oncologists

1 reference

https://pubmed.ncbi.nlm.nih.gov/24638849

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/24638849

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/24638849

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A Phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/24638849

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bone-targeted agent use for bone metastases from breast cancer and prostate cancer: A patient survey

1 reference

https://pubmed.ncbi.nlm.nih.gov/24638849

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A systematic review of dosing frequency with bone-targeted agents for patients with bone metastases from breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24638849

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10549-014-2906-X

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24638849%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24638849%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24638849%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37656386&oldid=2200740174"